1. Российские клинические рекомендации. Ревматология/ под ред. Е.Л. Насонова. – М.: ГЭОТАР-Медиа, 2017. 464 с. [Revmatologiya: Klinicheskie rekomendatsii. Moscow: GEOTAR-Media; 2017. 464 p.] 2. Алекберова З.С. Болезнь Бехчета: монография / З. С. Алекберова. — М.: 2007. 86 с. 3. Hatemi G., Seyahi E., Fresko I., Talarico R., Hamuryudan V. One year in review 2017: Beh?et’s syndrome. Clinical and Experimental Rheumatology 2017; 35 (Suppl.108): S3-S15. 4. Singer O. Cogan and Behcet Syndromes. Rheum Dis Clin N Am 41, 2015, 75–91 http://dx.doi.org/10.1016/j.rdc.2014.09.007 5. Zeidan M.J., Saadoun D., Garrido M., Klatzmann D., Six A., Cacoub P. Beh?et’s disease physiopathology: a contemporary review. Autoimmun Highlights, 2016 Dec; 7 (1): 4. DOI 10.1007/s13317-016-0074-1 6. International Society for Beh?et Disease. Официальный сайт: http://www.behcetdiseasesociety.org (http://www.behcetdiseasesociety.org) 7. Постановление Правительства РФ от 26.04.2012 № 403 «О порядке ведения Федерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболеваниями, приводящими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегмента». Официальный сайт правительства РФ: http://government.ru/docs/all/81971/ 8. International Study Group for Beh?et’s Disease. Criteria for diagnosis of Beh?et’s disease. Lancet 1990; 335: 1078-80. doi: http://dx.doi.org/10.1016/0140-736(90)92643-V 9. International Team for the Revision of the International Criteria for Beh?et’s Disease (ITR-ICBD). The International Criteria for Beh?et’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology, 2014, vol. 28, no. 3, pp. 338–347. 10. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Beh?et"s disease: international consensus recommendations. J Neurol. 2014 Sep; 261(9):1662-76. doi: 10.1007/s00415-013-7209-3. 11. Овчаров П. С., Лисицына Т. А., Вельтищев Д. Ю., Тардов М. В., Буренчев Д. В., Алекберова З. С., Насонов Е. Л. Неврологические и психические расстройства при болезни Бехчета. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6): 76-86 (http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2016/6/1199772982016061076) 12. Bhakta B.B, Brennan P, James T.E, Chamberlain M.A, Noble B.A, Silman A.J. Beh?et’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38: 728–33. (http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2016/6/1199772982016061076)http://dx.doi.org/10.1093/rheumatology/38.8.728 (http://dx.doi.org/10.1093/rheumatology/38.8.728) 13. Lawton G., Bhakta B. B., Chamberlain M. A., Tennant A. The Beh?et’s Disease Activity Index. Rheumatology 2004;43:73–78. doi:10.1093/rheumatology/keg453 14. Zouboulis C., Vaiopoulos G., Macromichelakis N. et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades – Behcet’s disease in Greece. Clin. Exp. Rheum. 2003, 21, (suppl.30) S19 - S26 15. Taylor J, Glenny AM, Walsh T, Brocklehurst P, Riley P, Gorodkin R, Pemberton MN. Interventions for the management of oral ulcers in Beh?et’s disease. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD011018. DOI: 10.1002/14651858.CD011018.pub2. 16. Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M. Behcet"s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017 Jan;13(1):57-65. Epub 2016 Jul 11. Review. DOI: 10.1080/1744666X.2016.1205486 (https://www.ncbi.nlm.nih.gov/pubmed/27351485) 17. Alpsoy E. Beh?et’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. (https://www.ncbi.nlm.nih.gov/pubmed/27351485)J Dermatol. (https://www.ncbi.nlm.nih.gov/pubmed/27075942) 2016 Jun;43(6):620-32. doi: 10.1111/1346-8138.13381. 18. Yazici H (https://www.ncbi.nlm.nih.gov/pubmed/? term=Yazici%20H%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Seyahi E (https://www.ncbi.nlm.nih.gov/pubmed/? term=Seyahi%20E%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Hatemi G (https://www.ncbi.nlm.nih.gov/pubmed/? term=Hatemi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=29296024), Yazici Y (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yazici%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=29296024) Beh?et syndrome: a contemporary view. Nat Rev Rheumatol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Hasan+Yazici+Beh%C3%A7et+syndrome%3A+a+contemporary+view+2018) 2018 Feb;14(2):107-119. doi: 10.1038/nrrheum.2017.208. 19. Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular Involvement of Beh?et’s Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. (https://www.ncbi.nlm.nih.gov/pubmed/24828904) 2015 Dec;49(3):298-306. doi: 10.1007/s12016-014-8425-z 20. Cunningham Et Jr, Tugal-Tutkun I, Khairallah M, Okada Aa, Bodaghi B, Zierhut M: Beh?et Uveitis. Ocul Immunol Inflamm 2017; 25: 2-6 21. Skef W, Hamilton MJ, Arayssi Th. Gastrointestinal Beh?et"s disease: A review World J Gastroenterol 2015 April 7; 21(13): 3801-3812. DOI: 10.3748/wjg.v21.i13.3801 22. Seyahi E: Beh?et’s disease: How to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol 2016; 30: 279-95 23. Kidd DP: Neurological complications of Beh?et’s syndrome. J Neurol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=KIDD+DP%3A+Neurological+complications+of+Beh%C3%A7et%E2%80%99s+syndrome.+J+Neurol+2017) 2017 Oct;264(10):21 2183. doi: 10.1007/s00415-017-8436-9 24. Leonardo N M, McNeil J. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Leonardo+N+M%2C+McNeil+J.+Behcet%E2%80%99s+Disease%3A) 2015; V. 2015, Article ID 945262, 7 pages. http://dx.doi.org/10.1155/2015/945262 (http://dx.doi.org/10.1155/2015/945262) 25. Demirseren D.D., Ceylan G.G., Akoglu G., Emre S., Erten S., Arman A., Metin A. HLA-B51 subtypes in Turkish patients with Beh?et’s disease and their correlation with clinical manifestations. Genetics and Molecular Research, 2014,13 (3): 4788-4796 DOI http://dx.doi.org/10.4238/2014.July.2.8 26. Алекберова З.С., Измаилова Ф.И., Гусева И.А., Денисов Л.Н., Глухова С.И., Попкова Т.В. HLA-B5/51-генотип: связь с клиническими проявлениями болезни Бехчета (https://elibrary.ru/item.asp?id=24157443). Научнопрактическая ревматология (https://elibrary.ru/contents.asp?id=34108832). 2015. Т. 53. № 4 (https://elibrary.ru/contents.asp?id=34108832&selid=24157443). С. 367-370. DOI; 10.14412/1995-4484-2015-367- 370 (https://doi.org/10.14412/1995-4484-2015-367-370) 27. Hatemi G, Christensen R, Bang D et al. 2018 update of EULAR recommendations for the management of Beh?et’s syndrome. Ann Rheum Dis 2018; 77: 808–818. doi: 10.1136/annrhumdis-2018-213225 28. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология 2015, Т.9, № 4, выпуск 2; с. 2-52. 29. Национальные рекомендации по ведению пациентов с аневризмами брюшной аорты. Ангиология и сосудистая хирургия 2013; Т. 19, № 2, приложение, с.2-74 30. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению взрослых больных язвенным колитом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2015; Т. 25, № 1, с.48-65 31. Ozguler Y, Hatemi G. Management of Beh?et’s syndrome. Curr Opin Rheumatol. (http://www.ncbi.nlm.nih.gov/pubmed/26555450) 2016 Jan; 28(1): 45-50. doi: 10.1097/BOR.0000000000000231. 32. Aktulga E, Alta? M, M?ft?oglu A, et al. A double blind study of colchicine in Beh?et’s disease. Haematologica 1980; 65: 399–402. 33. Yurdakul S, Mat C, T?z?n Y, et al. A double-blind trial of colchicine in Beh?et’s syndrome. Arthritis Rheum 2001; 44: 2686–92. 34. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Beh?et’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19: 542–9 35. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Beh?et’s syndrome. N Engl J Med Overseas Ed 1990; 322: 281–5. 36. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Beh?et disease: a randomized placebocontrolled and double-blind study. Arch Dermatol 2002; 138: 467–71. 37. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Beh?et’s disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98–105. 38. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh?et’s syndrome — a phase 2, placebo-controlled study. N Engl J Med Overseas Ed 2015; 372: 1510–8. 39. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh?et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443–50. 40. Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Beh?et’s disease with anakinra: a pilot open-label study. Arthritis Res Ther 2017; 19: 69. 41. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 2015; 34: 1293–301. 42. Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh?et’s disease: a multicenter retrospective study. Clin Rheumatol 2016; 35: 1281–6. 43. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120: 777–87. 44. Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Beh?et’s syndrome: report of two cases. Rheumatology 2013; 52: 1923–4. 45. Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Beh?et’s disease treated with tocilizumab. Clin Rheumatol 2015; 34: 1141–3. 46. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh?et’s disease: an open-label trial. Arthritis Rheum 2005; 52: 2478–84 47. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010; 94: 284–8. 48. Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Beh?et’s disease treated with interferon-alpha-2a. J Rheumatol 2008;35:896–903. 49. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh?et’s uveitis refractory to conventional treatments. Ophthalmology 2010;117: 1430–5. 50. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh?et’s disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31: 33–7. 51. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol 2011;95:205–8. 52. Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Beh?et’s disease using infliximab. Clin Exp Rheumatol 2011;29(4 Suppl 67): S58–63. 53. Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 2011; 95:1245–50. 54. Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Beh?et disease. Arch Ophthalmol 2012; 130: 592–8 55. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh?et’s disease: a multicenter study. Ophthalmology 2014; 121: 1877–84. 56. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/ or refractory Beh?et’s disease: Multicenter study of 124 patients. J Autoimmun 2015;62:67–74. 57. Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Beh?et’s uveitis: a retrospective longterm follow-up study. Clin Exp Rheumatol 2014;32(4 Suppl 84): S 58–62 58. Jaffe GJ, Dick AD, Br?zin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med Overseas Ed 2016; 375: 932–43. 59. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebocontrolled phase 3 trial. Lancet 2016; 388: 1183–92 60. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121:785–796. 61. Atmaca LS, Yal?inda? FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Beh?et’s disease. Graefes Arch Clin Exp Ophthalmol 2007;245:451–6. 62. Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh?et disease. J Ocul Pharmacol Ther 2007; 23:395–401. 63. Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Beh?et disease. Ocul Immunol Inflamm 2014; 22: 27–33 64. Grekas D, Nikolaidis P, Karamouzis M, et al. Effects of azathioprine on ciclosporin metabolism. Nephron 1992; 60: 489. 65. Seyahi E., Yurdakul S. Beh?et’s Syndrome and Thrombosis. Mediterr J Hematol Infect Dis 2011, 3: e2011026 DOI 10.4084/MJHID.2011.026 66. Tayer-Shifman OE, Seyahi E, Nowatzky J, et al. Major vessel thrombosis in Beh?et’s disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol 2012;30:735– 40. 67. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008;27:201–5. 68. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Beh?et’s disease. Arthritis Rheum 2012;64:2753–60. 69. Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Beh?et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine 2015;94:e494 70. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Beh?et syndrome. Am J Med 2004;117:867–70. 71. Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Beh?et?s syndrome: Effects of anti-TNF treatment. Semin Arthritis Rheum 2015;45:369–73 72. Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Beh?et disease: a series of 101 patients. Medicine 2012;91:18–24 73. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Beh?et disease: a series of 47 patients. Medicine 2012;91:35–48. 74. Park M-C, Hong B-K, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet’s disease. Clin Rheumatol 2007;26:1475–80 75. Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and longterm outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine 2016;95:e3348. 76. Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38–e45. 77. Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh?et’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol 2015;33(6 Suppl 94):S129–37. 78. Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol 2011; 30: 1007–12. 79. Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Beh?et disease. Neurol Neuroimmunol Neuroinflamm 2016;3: e258 80. Shugaiv E, Tu?zu?n E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011, 29 (4 Suppl 67): S64–S67 81. Kikuchi H, Aramaki K, Hirohata S Low dose MTX for progressive neuro-Behcet’s disease. A follow-up study for 4 years. Adv Exp Med Biol 2003, 528: 575–578 82. O’Duffy JD, Robertson DM, Goldstein NP Chlorambucil in the treatment of uveitis and meningoencephalitis of Behc,et’s disease. Am J Med 1984, 76: 75–84 83. Ait Ben Haddou EH, Imounan F, Regragui W et al. Neurological manifestations of Beh?et’s disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012, 168: 344–349 84. Noel N (http://www.ncbi.nlm.nih.gov/pubmed/? term=Noel%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Wechsler B (http://www.ncbi.nlm.nih.gov/pubmed/? term=Wechsler%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Nizard J (http://www.ncbi.nlm.nih.gov/pubmed/?term=Nizard%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Costedoat-Chalumeau N (http://www.ncbi.nlm.nih.gov/pubmed/?term=CostedoatChalumeau%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Boutin du LT (http://www.ncbi.nlm.nih.gov/pubmed/? term=Boutin%20du%20LT%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Dommergues M (http://www.ncbi.nlm.nih.gov/pubmed/? term=Dommergues%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Vauthier-Brouzes D (http://www.ncbi.nlm.nih.gov/pubmed/?term=VauthierBrouzes%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Cacoub P (http://www.ncbi.nlm.nih.gov/pubmed/?term=Cacoub%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23780828), Saadoun D (http://www.ncbi.nlm.nih.gov/pubmed/? term=Saadoun%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23780828). Beh?et"s disease and pregnancy. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/23780828#comments)Arthritis Rheum. (http://www.ncbi.nlm.nih.gov/pubmed/23780828) 2013 Sep; 65(9):2450-6. doi: 10.1002/art.38052. 85. Ben-Chetrit E (http://www.ncbi.nlm.nih.gov/pubmed/?term=BenChetrit%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25268664). Beh?et"s syndrome and pregnancy: course of the disease and pregnancy outcome. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/25268664#comments)Clin Exp Rheumatol. (http://www.ncbi.nlm.nih.gov/pubmed/25268664) 2014 Jul-Aug; 32 (4 Suppl 84):S93-8. 86. Hamza M., Ellench M., Zribi A. Behcet’s disease and pregnancy. Ann. Rheum. Dis. 1988, 47: 350 87. Jadaon J (http://www.ncbi.nlm.nih.gov/pubmed/? term=Jadaon%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Shushan A (http://www.ncbi.nlm.nih.gov/pubmed/? term=Shushan%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Ezra Y (http://www.ncbi.nlm.nih.gov/pubmed/?term=Ezra%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Sela HY (http://www.ncbi.nlm.nih.gov/pubmed/? term=Sela%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Ozcan C (http://www.ncbi.nlm.nih.gov/pubmed/?term=Ozcan%20C%5BAuthor%5D&cauthor=true&cauthor_uid=16167908), Rojansky N (http://www.ncbi.nlm.nih.gov/pubmed/? term=Rojansky%20N%5BAuthor%5D&cauthor=true&cauthor_uid=16167908). Beh?et"s disease and pregnancy. See comment in PubMed Commons below (http://www.ncbi.nlm.nih.gov/pubmed/16167908#comments)Acta Obstet Gynecol Scand. (http://www.ncbi.nlm.nih.gov/pubmed/16167908) 2005 Oct;84(10):939-44.